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Background: Physical exercise training aims at reducing disease-specific impairments and improving quality of life in
patients with chronic obstructive pulmonary disease (COPD). COPD exacerbations in particular negatively impact COPD
progression. Physical therapy intervention seems indicated to influence exacerbations and their consequences. However,
information on the effect of physical therapy on exacerbation occurrence is scarce. This study aims to investigate the
potential of a protocol-directed physical therapy programme as a means to prevent or postpone exacerbations, to
shorten the duration or to decrease the severity of exacerbations in patients with COPD who have recently experienced
an exacerbation. Besides, this study focuses on the effect of protocol-directed physical therapy on health status and
quality of life and on cost-effectiveness and cost-utility in patients with COPD who have recently experienced an
exacerbation.
Methods/Design: A prospective cohort of 300 COPD patients in all GOLD stages will be constructed. Patients will receive
usual multidisciplinary COPD care including guideline-directed physical therapy. Patients in this cohort who have GOLD
stage 2 to 4 (post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80% of predicted), who receive reimbursement by health
insurance companies for physical therapy (post-bronchodilator Tiffeneau-index < 0.6) and who experience a COPD
exacerbation will be asked within 56 days to participate in a cohort-nested prospective randomised controlled trial
(RCT). In this RCT, the intervention group will receive a strict physical therapy programme for patients with COPD. This
protocol-directed physical therapy (pdPT) will be compared to a control group that will receive sham-treatment,
meaning no or very low-intensity exercise training (ST). An economic evaluation will be embedded in the RCT.
Anthropometric measurements, comorbidities, smoking, functional exercise capacity, peripheral muscle strength,
physical activity level, health related quality of life, patients’ perceived benefit, physical therapy compliance,
motivation level, level of effective mucus clearance, exacerbation symptoms and health care contacts due to COPD
will be recorded. Follow-up measurements are scheduled at 3 and 6 weeks, 3, 6, 12 and 24 months after inclusion.
Discussion: Ways to minimise potential problems regarding the execution of this study will be discussed.
Trial registration: The Netherlands National Trial Register NTR1972.
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Chronic obstructive pulmonary disease (COPD) is cur-
rently defined as “a common preventable and treatable
disease, characterised by persistent airflow limitation
that is usually progressive and associated with an en-
hanced chronic inflammatory response in the airways
and the lung to noxious particles or gasses. Exacerba-
tions and comorbidities contribute to the overall severity
in individual patients” [1]. The World Health Organisa-
tion (WHO) lists COPD as the tenth most prevalent dis-
ease worldwide and the fourth most common cause of
death in the world, responsible for 5% of overall mortal-
ity [2]. Due to the ageing population, expanding smoking
behaviour, earlier diagnosis of COPD and reduced mor-
tality from other common causes of death, the total
number of people with COPD will increase in the near
future. This will rank COPD fifth worldwide in burden
of disease by 2020 [1].
Common clinical pulmonary manifestations that can
be seen in COPD patients are dyspnoea with chronic
cough, sputum production and recurrent respiratory in-
fections. Additionally, with disease progression signifi-
cant extrapulmonary systemic effects can be observed in
patients, especially in patients with moderate to severe
airway obstruction: skeletal muscle dysfunction and
weakness, nutritional abnormalities and weight loss
[1,3]. Nowadays, systemic effects of COPD are acknow-
ledged as an important characteristic of the disease, which
contribute significantly to decreased exercise capacity, de-
creased health status, reduced health related quality of life
(HRQL), more utilisation of health care resources and in-
creased mortality [3-5].
The impact of COPD exacerbations
The definition of COPD by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) explicitly
mentions COPD exacerbations as an enormous burden
for patients [1] and health care systems [6]. Exacerba-
tions are defined as “an event in the natural course of
the disease characterised by an increase in dyspnoea,
cough and/or sputum beyond normal day-to-day varia-
tions. The onset is seemingly acute and may require a
change in regular medication or hospitalisation” [1,7].
They are mostly precipitated by an infectious systemic
inflammation of the upper respiratory tract and the tra-
cheobronchial tree [1].
Since exacerbations are a significant cause of morbidity
(e.g. acute muscle deconditioning and muscle weakness),
hospital admissions, impaired health status, impaired
quality of life and even death in patients [8-10], prevention
is indicated. A relatively small percentage of patients
(10%) experiencing frequent exacerbations account for
over 70% of all medical costs due to COPD [6]. A study of
Pitta et al. (2006) showed that COPD patients tend to beseverely inactive during and after an exacerbation; which
is worrying since there seems to be a strong association
between physical inactivity in patients who recently exac-
erbated and an elevated risk of (re)hospitalisation due to a
COPD exacerbation [11,12]. It appears that patients with
recurrent exacerbations show a more rapid decline in their
physical activity level than stable patients and their func-
tional capacity gradually decreases faster over time [11].
Besides, their more pronounced skeletal muscle weakness
and decreased six-minute walk distance (6MWD, a
measure of functional exercise capacity), are risk fac-
tors for future exacerbations and higher mortality [9,13].
Consequently, unstable patients, who frequently expe-
rience exacerbations, enter a downward spiral of inactivity
and exacerbations. Hence, adequate management of ex-
acerbation (prevention) in patients is considered world-
wide as one of the main goals in controlling COPD [1].
Although medical treatment modalities for COPD
have improved, there is still no pharmacological therapy
available that reduces the progression of the disease [4].
Though, patients with COPD, irrespective of disease
stage, have shown to benefit from exercise programmes
[12] resulting in improved exercise performance and
health status [4,5,14-17].
Physical exercise training in COPD
Evidence, to support the biological plausibility of the
positive effects of physical exercise training on COPD,
points towards longer high-intensity exercise training
programmes. High-intensity exercise training has shown
to increase exercise tolerance [18,19]. Firstly, exercise
training improves muscle oxidative capacity and oxygen
recovery kinetics in patients with COPD [20]. Secondly,
patients with COPD who experience lactic acidosis du-
ring exercise can attain physiologic training responses
from a physical exercise training programme [21,22].
Exercise performance can be improved by reducing the
ventilatory requirement for a certain activity level. As
the bioenergetics of skeletal muscle improve, blood lac-
tate levels are reduced at a given level of exercise;
thereby decreasing the amount of non-metabolic carbon
dioxide (CO2) that is produced by the bicarbonate buff-
ering system [12,21]. Since lactic acid stimulates ventila-
tion, decreasing lactate production during exercise can
be very helpful for patients with COPD. Physical exercise
training, in addition to optimal bronchodilatation, can
reduce breathing frequency during exercise and conse-
quently lower the degree of dynamic lung hyperinflation
that many patients with severe COPD develop [22,23].
In turn, decreased hyperinflation may mediate improve-
ment in exercise endurance by delaying the attainment
of a critically high inspiratory lung volume [22,23].
Moreover, high-intensity exercise training, engendering
high levels of blood lactate, are more effective than
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though measurable physiological changes may occur
within weeks, behavioural changes may require longer
time periods and may be the reason that greater effects
were shown in long-term exercise programmes [19]. In
conclusion, extensive physical exercise training is benefi-
cial in patients with COPD.
Physical exercise training to reduce COPD exacerbation
frequency, duration or severity
Patients with COPD often experience sudden worsening
of symptoms, i.e. exacerbations. Previous studies already
demonstrated that physical exercise training (the com-
ponent that has shown to provide the most benefit of
pulmonary rehabilitation programmes) [1] has important
benefits for patients, such as improved exercise capacity
and HRQL [9,15,24]. However, the effect of pulmonary
rehabilitation and physical exercise training on the
occurrence of exacerbations is less clear [4,19,25,26].
Observational studies demonstrated that patients who
perform regular physical activity have a reduced risk of
hospital admission due to COPD and decreased all-
cause and respiratory mortality [12,27,28], but neither of
these outcomes are a substitute for reduction of exacer-
bation frequency, duration or severity. The factors deter-
mining utilisation of health care resources in patients
with COPD are poorly understood [29]. Few studies re-
ported significantly fewer exacerbations after a pulmon-
ary rehabilitation program (including physical exercise
training) [30,31]. Reduction of exacerbations may be at
least one of the factors explaining the reduction in
health care utilisations as reported in observational stud-
ies. Moreover, a recent study suggested that an acute
bout of exercise resulted in a reduction in sputum proin-
flammatory cytokines, suggesting some anti-inflammatory
effect of exercise in the airways of patients with COPD
[32]. Based on these few findings it is plausible to hy-
pothesise that physical exercise training for patients with
COPD may result in fewer exacerbations, or at least in
less severe exacerbations, meaning exacerbations with a
shorter duration or exacerbations without the necessity
for hospital admission.
Prevention of exacerbations by means of physical exer-
cise training would fit the prime management goal for
COPD [27]. Based on expert’s opinion, it was stated that
teaching patients how to recover quickly from an exacer-
bation will probably minimise the risk for relapse and
improve long-term outcome [26]. Exercise training im-
proves recovery in patients with COPD after an acute
exacerbation [33]. Also, from previous studies it has
been shown that especially early pulmonary rehabili-
tation (including physical therapy) after an acute ex-
acerbation is most likely to result in clinically relevant
improvements in functional exercise capacity andhealth-related quality of life [5,16]. Puhan et al. (2011)
found in nine small trials of moderate methodological
quality that effects of pulmonary rehabilitation pro-
grammes immediately after an acute COPD exacerbation
were visible when at least physical exercise was included
[24]. However, they also concluded that more studies are
needed to further investigate the role of pulmonary re-
habilitation after an acute exacerbation and its potential
to reduce costs [24,34].
Evidence based physical exercise training and advice
on physical activity can be delivered by physical thera-
pists that follow evidence based guidelines for physical
therapy in COPD patients, such as the guideline COPD
developed by the Royal Dutch Society for Physical Ther-
apy (KNGF) [35]. This study protocol hypothesis that
early protocol-directed physical therapy for patients with
COPD may reduce COPD exacerbation frequency, dur-
ation or severity.Methods/Design
Study aim
The aim of this study is to assess the clinical effectiveness,
cost-effectiveness and cost-utility of early protocol-direc-
ted physical therapy for patients with COPD on exacerba-
tions (frequency, duration and severity), health status and
quality of life in patients who have recently experienced a
COPD exacerbation.Study design
A cohort-nested, prospective, randomised controlled
trial (cohort-nested RCT) will be conducted. This means
that a RCT will be embedded within a COPD cohort
(Figure 1). The cohort will consist of COPD patients
who receive usual multidisciplinary COPD care and
guideline-directed physical therapy (gdPT). The cohort
will serve as an optimal recruitment population for the
RCT to show the surpassing importance of physical
therapy interventions on exacerbations. Therefore, a
RCT that holds a large contrast of protocol-directed
physical therapy (pdPT) versus sham treatment (ST) will
be constructed. This means that when patients from the
COPD cohort report an exacerbation, with an occurrence
no longer than 56 days ago (a trade-off between threshold
values of 35–91 days in which the majority of exacer-
bations have returned to baseline [36]), they are either
randomised to the experimental group (protocol-directed
physical therapy (pdPT)) or the control group (sham-
treatment (ST)). This RCT will be used to study effec-
tiveness of physical therapy in addition to an economic
evaluation.
The ethics committee of Maastricht University has ap-
proved the study protocol, procedures and informed
consent (NL28718.068.09).
Figure 1 Framework of the study: a cohort-nested, prospective, randomised controlled trial. Definition of abbreviations: COPD = Chronic
Obstructive Pulmonary Disease; RCT = Randomised Controlled Trial; Tiffeneau < 0.6 = Tiffeneau index (FEV1/VC) < 0.6*; FEV1 = Forced Expiratory
Volume in one second*; FVC = Forced Vital Capacity*; GOLD I = mild COPD, FEV1/FVC < 0.7 and FEV1 ≥ 80% of predicted*; GOLD II = moderate
COPD, FEV1/FVC < 0.7 and 50%≤ FEV1 < 80% of predicted*; GOLD III = severe COPD, FEV1/FVC < 0.7 and 30%≤ FEV1 < 50% of predicted*; GOLD IV
= very severe COPD, FEV1/FVC < 0.7 and FEV1 < 30% of predicted or FEV1 < 50% of predicted* plus chronic respiratory failure. *All lung functions
are post-bronchodilator values.
Figure 2 Flowchart of the RCT. Definition of abbreviations:
COPD= chronic obstructive pulmonary disease; pdPT = protocol-directed
physical therapy; ST = sham-treatment, including no or very low-intensity
exercise training.
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The study population consists of patients who are
treated by COPD-specialised physical therapists, after re-
ferral by a general practitioner (GP) or pulmonologist.
Physical therapy practices, GPs and pulmonologists, in
southern districts of the Netherlands, who are willing to
participate in the study, will be recruited. Once a patient
is referred to a participating physical therapy practice
(with post-bronchodilator FEV1/FVC < 0.7, GOLD 1–4),
the patient will be asked to participate in the COPD co-
hort study. Patients in the cohort are monitored for
health outcomes and exacerbation occurrence. Partici-
pants for the RCT will be recruited within the cohort by
physical therapists, as soon a patient suffers from an ex-
acerbation. Additionally, advertisements in local papers
in southern regions of the Netherlands are used to reach
potential COPD patients for the RCT who were missed
out on inclusion with the former recruitment method.
Those patients who are reached through advertising and
presenting with an exacerbation will be recruited for the
RCT by the researcher, while the mechanisms for alert
and continuous trial recruitment are automatically orga-
nized within the cohort. By means of this unique cohort-
nested RCT design (Figure 1), the likelihood that patients
with a COPD exacerbation will be picked up is higher. A
flowchart of the RCT is presented in Figure 2.
The following inclusion criteria will be checked during
the eligibility screening of patients for the RCT: a GP/pul-
monologist diagnosed COPD in GOLD stage 2, 3 or 4
(supported by a post-bronchodilator FEV1/FVC < 0.7 and
FEV1 < 80% of predicted); eligible for reimbursement by
health insurance companies for physical therapy (post-
bronchodilator Tiffeneau-index < 0.6); experienced an
COPD exacerbations in the past 56 days (defined as: un-
scheduled visit to their GP/pulmonologist or hospitalisationand possibly receiving a course of antibiotics and/or pred-
nisone); having an adequate and optimal medication (in-
halation) regimen by their referring physician; willing to
sign informed consent before randomisation; competent
enough to speak and understand the Dutch language;
above 18 years of age.
Patients who meet the following criteria will be ex-
cluded from the RCT: suffering from significant exercise
limitations or comorbidities that would prevent a patient
from following the required intervention in this study;
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cause of a planned change of residency).
All patients entering the cohort have to give informed
consent on the following two levels, whereas patients
entering the RCT have to give informed consent on
three levels: (1) oral consent to exchange patient infor-
mation between physical therapists and other related
health care providers (usual physical therapy procedure);
(2) oral consent to participation in the COPD cohort
(registration and use of data for research purposes); and
(3) written consent to participate in the RCT, after ex-
periencing an acute exacerbation.
Size of the study population
For the cohort study 300 patients with COPD will be re-
cruited. This number is based on the calculated sample
size for the RCT part of the study. The sample size cal-
culation for this RCT is based on the identification of a
minimal relevant clinical difference in exacerbation fre-
quency between the experimental and the control group.
The difference in exacerbation rate is expected to be
22% (based on exacerbation rates found in previous
studies with rehabilitation programmes) [37,38]. The
probability that the study will detect a treatment differ-
ence is 80% at a two-sided 5% significance level. This is
based on the assumption that the intervention period
will be 12 months, the follow-up period will be
24 months and the ratio control subjects to intervention
subjects is 1:1. A sample size calculation for comparing
event rates between two independent groups is used,
resulting in 79 participants per group [39,40]. Assuming
outcome data will be analysed prospectively and consid-
ering a drop-out rate of 20%, 100 patients per group will
be needed in this two treatment parallel-design study.
Randomisation and blinding
After taking baseline measurements and eligibility screen-
ing within 56 days after the start of the past exacerbation,
informed consent is obtained and stratified block rando-
misation will take place (Figure 2). Pre-stratification will
be applied for exacerbation severity and GOLD stage (six
levels in total), since both factors are suspected to in-
fluence treatment outcome. Therewith, the influence of
selection bias for severity of the disease on group config-
uration or comparability between groups may be mini-
mized. The patients will be randomly assigned to the
experimental group or the control group in a 1:1 ratio.
The concealed randomisation procedure will be per-
formed by a blinded, independent research assistant using
a computerised system. A block-randomisation will be
used with blocks of size four, six or eight, with random
block sequences. A computerized system will refer the pa-
tients to a group, after which a blinded, independent re-
search assistant will notify the treating physical therapistafter receiving instructions on treatment group allocation
through computer generated random number tables.
In this RCT full blinding of the patients and physical
therapists is not feasible. However, Hawthorne effects
are non-differential, since patients in the experimental
group as well as patients in the control group will get at-
tention from their physical therapist. Both groups re-
ceive periodic questionnaires and measurement sessions,
avoiding non-random effect optimisation. Several mea-
sures are taken to avoid bias due to blinding issues. Al-
though patients will be aware of the existence of two
treatment arms, they are not informed about the exact
content of the other treatment arm (e.g. determining in-
tensity) to prevent influence on outcomes. The control
group will be assessed at the same time intervals as the
experimental group by trained physical therapists that
do not assess the patients in the experimental group at
the same time. The researcher is fully blinded, because
all outcome measures are quantified by the patients and
physical therapists. Physical therapists are blinded for a
number of outcomes measurements (questionnaires
CCQ, CRQ-SR, GPE, EQ-5D, DS14 and physical activity
level), since part of the data that are provided by the pa-
tient alone and will be captured through an electronic
patient record system. Moreover, a number of important
objective outcomes (exacerbation frequency, duration
and severity, mechanically assessed physical activity level
and cost diaries) are less liable to patient manipulation
in order to please their physical therapist, as these out-
comes are directly collected by the researcher.
Cohort
All participants in the cohort receive usual multidiscip-
linary COPD care including guideline-directed physical
therapy. In the Netherlands usual COPD care is given by
a pulmonologist and/or a GP. This usual COPD care en-
tails lung function testing, medication prescription for
COPD and counselling, including education about the
disease, symptoms and risks and tailor-made advice,
which basically comes down to two major aspects; stop
smoking and increase physical activity in everyday life
[41]. In the light of the latter, all patients in the cohort
are referred for usual physical therapy and physical ac-
tivity advice. Usual physical therapy in the Netherlands
is guideline-directed physical therapy (gdPT), provided
by registered physical therapists and based on the KNFG
physical therapy guidelines for COPD [35]. These guide-
lines provides assistance for applying physical therapy
intervention (diagnosis and treatment) in COPD patients
coping with impairments in mucus clearance, pulmonary
function, muscle function and exercise capacity, and
with limited physical activities due to dyspnoea or
exercise intolerance. In the guidelines the effectiveness
of several treatment modalities (specifically exercise
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muscle training) was reported and evidence based rec-
ommendations for the application of these modalities in
physical therapy programmes were made. Moreover, dis-
ease management strategies are integrated. Short term
goals incorporate improvement of patient’s knowledge,
self-management and confidence to accomplish activi-
ties. Medium term goals are relief of dyspnoea, im-
provement of impaired airway (mucus) clearance, and
improving or retaining exercise performance and phy-
sical activity in everyday life [35]. Long term goals entail
improvement or preservation of disease related quality
of life. Physical therapists are free to compile a patient-
centred program at one’s professional discretion, within
the limitations of the guideline. Hence, frequency of the
guideline-directed physical therapy for COPD in the
Netherlands varies; patients visit their physical therapist
generally one to three times a week, for one hour, ranging
from one-time consultation to multiple consultations dur-
ing 3–12 months, depending on disease severity (based on
usual care given in participating physical therapy prac-
tices) (Table 1).Randomised controlled trial
As patients enter the RCT, after experiencing a COPD ex-
acerbation, they may be assigned to either the experimentalTable 1 Contrasts between RCT experimental and control gro
Intervention Content
Cohort Guideline-directed physical
therapy (gdPT):
One or more of:
Exercise training, periphera
strength training, respirator
training, breathing exercise
muscle stimulation, physica
daily life (homework)
A programme made by
individual PTs, within the
limitations of the KNFG physical
therapy guideline for COPD
(usual care)
RCT
experimental
group
Protocol-directed physical
therapy (pdPT):
Both exercise training and
peripheral muscle strengt
A complete programme by
protocol, according to the KNGF
physical therapy guideline for
COPD, but with strict conditions
When indicated: respirato
training, breathing exerci
electrical muscle stimulat
Always: physical activity i
(homework)
RCT control
group
Sham-treatment (ST): One-time consultation: ad
be physically active in da
No physical therapy
Or
Very low-intensity exercise
training
Exercise training only
Definition of abbreviations: RCT = randomised controlled trail; COPD = chronic obstrgroup or control group. Contrasts between the experi-
mental group, control group and the cohort, based on
content, intensity, frequency and timing, are displayed in
Table 1.Experimental group
Patients in the experimental group receive protocol-
directed physical therapy (pdPT). The content of the
pdPT is based on the on the KNGF physical therapy
guidelines for COPD, like the guideline-directed physical
therapy in the cohort [35]. However, in the RCT the
physical therapy follows a strict protocol. The therapy
specifically concerns early physical therapy, starting
within 56 days after an acute COPD exacerbation. Pa-
tients in the experimental group receive a programme of
one hour, twice a week for one year. The programme in-
cludes high-intensity exercise training, which entails en-
durance and/or interval training with an intensity of
60% or higher of (sub) maximum physical exertion,
based on the results of a maximal cardiopulmonary exer-
cise test (CPET) and six-minute walk test. In addition,
ratings of perceived exertion and dyspnoea of five or
higher on the modified Borg-scale (0–10) are used to
tailor exercise intensity [42]. Peripheral muscle strength
training is provided (a programme combining upper and
lower extremities) with an intensity of 80% or higher ofup and cohort
Intensity Frequency Start
Ranging on the full intensity
scale
On average:
l muscle
y muscle
s, electrical
l activity in
30 minutes to
1 hour
1 to 3 times a
week
During 3
months to
multiple years
h training;
Endurance/ interval training
≥ 60% of (sub) maximum,
muscle strength training
≥ 80% of maximum, always:
borg-scale ≥5
Minimal: Early PT:
starting within
56 days after an
acute
exacerbation
1 hour
Twice a weekry muscle
ses,
ion During 12
months
n daily life
vice to
ily life
Maximal:
Endurance/ interval
training ≤ 15% of (sub)
maximum or borg-scale ≤2
30 minutes
Once a week
During 12
months
uctive pulmonary disease; KNGF = the Dutch Society for Physical Therapy.
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repetition maximum tests or handheld dynamometer
measurements. Again, ratings of perceived exertion and
dyspnoea of five or higher on the modified Borg-scale
are used to adjust exercise intensity [9]. When indicated,
the programme includes respiratory muscle training,
breathing exercises and electrical muscle stimulation. In
addition, much emphasis is given to the assessment and
treatment of physical inactivity in daily life. Patients are
asked to increase their total physical activity on their
own. At least 30 minutes of moderately intense physical
activity on at least five days a week is the current recom-
mended level. All visits for treatment and all advice for
home training are part of standard procedure, following
the KNGF guideline physical therapy for COPD and the
Dutch Standard for Healthy Exercise (NNGB) [35,43].
An additional file shows the intervention in more detail
according to a framework based on the International
Classification of Functioning, Disability and Health (ICF)
[see Additional file 1] [44].
Control group
Patients in the control group receive sham-treatment
(ST), which entails no or very low-intensity exercise
training, for one year. The latter applies only if the par-
ticipant in the control group insists on training in a
physical therapy practice. The very low-intensity exercise
training is limited to a maximum of 30 minutes once a
week, with an intensity of 15% or lower of (sub) maxi-
mum physical exertion, based on the results of a maxi-
mal CPET and six-minute walk test. In addition, ratings
of perceived exertion and dyspnoea of two or lower on
the modified Borg-scale (0–10) are used to tailor exer-
cise intensity [42]. There will be no further peripheral
muscle strength training, respiratory muscle training,
breathing exercises nor electrical muscle stimulation
[35]. Furthermore, patients will be advised to do at least
30 minutes moderately intense physical activity on their
own for at least five days a week according to the phys-
ical activity norm [43].
Physical therapists
All interventions are carried out in primary care physical
therapy practices. Registered physical therapists, experi-
enced in COPD care, who are willing to participate in
the study, will be recruited through local physical ther-
apy networks in the Netherlands that already have
mapped the specialised skills of these health profes-
sionals and registered who treats a sufficient number of
patients with COPD (with a minimum of 5–10 per
week).
Therapists will be invited to attend information/train-
ing sessions given by the research group and related
COPD experts. Information will be given about the aimand content of the cohort and RCT along with informa-
tion about the necessary clinical measurements. Lectures
will be given on the latest information on COPD and
updates on the current COPD guidelines and on coun-
selling (in line with the Dutch college of general practi-
tioners (NHG) standard COPD). Furthermore, a COPD
master class will be given to the network of participating
physical therapists in cooperation with the Dutch Para-
medical Institute (NPi).
Data collection
Participants will be monitored by physical therapists
with the help of a high quality electronic patient record
system that is COPD-specific and serves simultaneously
as a research database for the experimental group as well
as for the control group. Moreover, the system will be
used by physical therapists as guidance for treatment of
the experimental group, since the KNGF guidelines
physical therapy for COPD is fully incorporated within
this system (for example: an alert will be visible on the
computer screen when a patient’s performance is below
80% of the predicted peripheral muscle strength or when
FEV1 <50% and Medical Research Council dyspnoea
score (MRC) ≥2 an advice to initiate multidisciplinary
evaluation and rehabilitation is given).
Primary and secondary study-specific outcome mea-
sures will be assessed with the help of the COPD-
specific record system. In addition, the system will con-
tain information about the content of physical therapy,
the duration of physical therapy, the total amount of
physical therapy sessions, the duration per session, and
the adherence to physical therapy.
Primary outcome measure
The primary outcome measure will be exacerbation fre-
quency, calculated as the number of COPD exacerba-
tions experienced by the patient in a post exacerbation
period of two years. A COPD exacerbation will be iden-
tified as a sustained worsening of the patient’s condition
occurs from the stable state and beyond normal day-to-
day variations that is acute in onset and may warrant
additional treatment [45]. A recurrent exacerbation will
be defined as a subsequent occurrence; exacerbations
are assumed to be independent of each other. The
follow-up period is twelve months (twenty-four months
for the long-term outcome measurement) to overcome
time confounding, since exacerbation frequency is sea-
sonal and particularly related to influenza and other viral
epidemics [45].
In the cohort, exacerbations will be identified by
means of an event based approach, whereas in the RCT
exacerbations will be identified by means of an event
based approach (health care contact) and symptom
based approach (clear increase of respiratory symptoms).
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health care contacts. However, there are many underre-
ported exacerbations in COPD patients when using this
event based method [46]. On average, these underre-
ported exacerbations have similar severities to reported
exacerbations [45]. Therefore, increase of respiratory
symptoms will also be recorded in the RCT. When
measuring the appearance of exacerbations with these
two methods, this trial is able to compare event based
and symptoms based methods in relation to the primary
and some of the secondary outcome measures.
1. Event based approach
The onset of an exacerbation will be the first day of an
unscheduled health care contact with a GP/pulmonolo-
gist due to a COPD exacerbation and the start of
additional medication intake or the first day of an un-
scheduled hospitalisation or emergency visit to the hos-
pital due to an exacerbation. The exacerbation lasts until
the last day of this extra medication intake or until the
last day of hospital admission [45]. To identify these
events, physical therapists will monitor patients’ reasons
for absenteeism on physical therapy appointments and
relapse in treatment (as an exacerbation might be the
reason). In addition, records of health care contacts and
additional medication use due to COPD are registered
on patients’ prospective daily diary cards. Overall, good
compliance to register for instance symptoms, can be
achieved using daily diaries in COPD [47].
2. Symptom based approach
Respiratory symptoms will be monitored using pro-
spective daily diary cards. In these diary cards pa-
tients have to report, according to Anthonisen et al.
(1987), whether their major symptoms (breathlessness,
sputum production, sputum colour) and minor symp-
toms (cough, wheeze, running nose, score throat, and
fever (>38.5°C) were beyond normal [7]. Prospective
diary card assessments are best recorded as changes
from an agreed baseline, rather than absolute symp-
tom severities. Comparable to the COPE-II study by
Effing et al. (2009), at inclusion all patients will re-
ceive a ‘what is normal for me’ card, which describes
their individual levels of major symptoms at baseline
[48]. When patients experience no deterioration of
any of the symptoms listed on the diary, they should
check ‘no change in symptoms’. When patients ex-
perience deterioration, they should check ‘yes’ and re-
port on all symptoms in the diary whether the level
of each symptom was ‘normal’, ‘slightly increased’, or
‘clearly increased’.
The onset of an exacerbation will be defined as the
first day of at least two consecutive days at which the
patient checks ‘clear increase’ from baseline in twomajor symptoms or one major and one minor symp-
tom. The day that an exacerbation is resolved will be
defined as the first day of: (1) three successive days
that the patient has returned to his normal health state;
or (2) seven consecutive days on which patients con-
tinuously reported no or only a ‘slight increase’ in
symptoms, compared to baseline, with no fever or
change in sputum colour [7,48,49]. Besides the daily
diary card, symptoms during COPD exacerbations will
also be recorded by the physical therapists, in order to
receive additional information about the number and
type of perceived symptoms and to add missing infor-
mation to the daily diary cards in cooperation with the
patient.
Secondary outcome measures
Exacerbation duration is defined as the duration of the
medical intervention per occurrence and the number of
days with clear increase of respiratory symptoms. For
the event based approach: the duration of an exacerba-
tion will be equal to the time of the medical intervention
[45]. For the symptom based approach: the duration of
an exacerbation will be equal to the time between onset
and resolution of exacerbation based on the above men-
tioned definitions [7,48,49].
Furthermore, a distinction is made between various
levels of exacerbation severity. For the event based ap-
proach, a scale for exacerbation severity is proposed,
which distinguishes two levels of exacerbation severity:
(1) mild/moderate and (2) severe. Level one exacerba-
tions can be treated at home by means of a health care
contact with a GP/pulmonologist and the start of add-
itional (temporarily) medication intake (e.g. corticoste-
roids or antibiotics). Level two exacerbations require
hospitalisation or an emergency visit to the hospital
[45,46]. For the symptom based approach: the severity of
an exacerbation day will be calculated with help of
symptom scores. The major symptoms are scored as:
normal = 0; small increase = 1; or clear increase = 2. The
minor symptoms are scored 0, 0.5 and 1, respectively.
Sputum colour will be scored as: normal = 0, different
from normal = 2; and fever: no = 0, yes = 1. Adding all
scores, results in a daily symptom score ranging from
0–11 points. When patients are admitted to the hospital
for their COPD, a daily score of the maximum 11 points
will be assigned [7,48].
Generic health related quality of life (HRQL) of the
patients will be assessed by means of the Euro-Qol
(EQ-5D-3L). Disease-specific HRQL will be assessed
with the Clinical COPD Questionnaire (CCQ) and the
Chronic Respiratory Questionnaire – self reported
(CRQ-SR). In addition, negative affectivity, social inhib-
ition, and type D personality will be assessed by means
of the DS14 questionnaire.
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ance, physical activity in daily life and motivation will be
assessed by standardised questions from the KNGF
guidelines [35]. Furthermore, to estimate the patients’
perceived benefit of the physical therapy, the Global
Perceived Effect (GPE) will be scored by patients on a
9-point scale [35]. Objective assessment of physical
activity in daily life will be done by means of an
accelerometer-based activity monitor (Dynaport Move-
Monitor) [50].
Height, weight, Body Mass Index (BMI) and Fat Free
Mass (FFM) will be measured. The peripheral muscle
strength of the patient will be measured as maximal vo-
luntary isometric contraction (MVIC) of the dominant
hand, shoulder abduction and knee extension (m. quad-
riceps), tested in standardised positions by means of the
break method by a handheld dynamometer [42,51].
Functional exercise capacity is measured by the six-
minute walk test (6MWT), in accordance with the
guidelines by the American Thoracic Society [52]. If
a straight floor-walking course of 30 metres is not
available in the physical therapy practice, a course with
a distance of 10 metres is the required minimum [35].
Outcome is measured by total walking distance in me-
tres (6MWD) and in percentage of the predicted value.
Reference equations by Hill et al. (2011) will be applied
to calculate the predicted value if a straight 30 metre
walking course was used, whereas reference equations
for a straight 10 metre walking course may be necessary
to develop within this study, as no reference equations
exist for this frequently used test layout [53]. During the
walk test, perceived fatigue and dyspnoea will be
measured on a modified Borg scale ranging from zero
(nothing at all) to ten (very, very severe) [42]. Transcu-
taneous oxygen saturation and pulse rate will be mea-
sured with a finger pulse oximeter (Onyx 9500) [52].
The modified Get Up and Go test (mGUG) is used to
measure basic functional mobility. The outcome is the
time it takes a subject to stand up from a chair and
walk a distance of 10 metres [54]. After the mGUG,
perceived exertion is measured with the modified Borg
scale.
Comorbidities of all participants will be recorded
thoroughly, as well as smoking history (pack years and
cessation moment) and physical therapy compliance
(scored by the therapist as insufficient, moderate or
good and scored whether comorbidity has any influence
on this compliance), as being important potential con-
founders in this study. Number and type of adverse
events will be registered during the one-year treatment
period. After randomisation, patients are discouraged to
participate in interventions other than those in the
study (like hydrotherapy or drug studies) that may in-
fluence the outcome measures. When they still decideto participate in other interventions, these interventions
will be registered during the study period.
Finally direct and indirect costs will be assessed with
three-monthly retrospective questionnaires, including
questions about health care contacts, medications use,
residential status, occupational status, domestic care
service and use of medical aids. The economic eva-
luation will be analysed from a societal perspective. This
means that the most appropriate set of costs captured
from the data, regardless of where the costs or benefits
occur, will be applied.
Planning of outcome assessment
In all eligible patients, entering the cohort and the RCT,
baseline assessment will be performed. In the base-
line assessment, demographic variables, anthropometric
data, healthcare/medical variables, lifestyle factors,
health related quality of life and clinical status will be
recorded of the participants.
The lung function of the patients is already assessed
by the GP/pulmonologist or assistant, by means of pul-
monary function tests, as part of standard procedure in
patients with COPD. Forced expiratory volume in one
second (FEV1 (L)), forced vital capacity (FVC (L), the
FEV1/FVC ratio and Tiffeneau-index (FEV1/VC) are
measured by means of post-bronchodilator spirometry
and are known to the physical therapist in order to con-
struct a tailored-made programme adjusted to the se-
verity of the pulmonary component of the disease. The
clinical status, maximal exercise capacity and physio-
logical restrictions of the patients should in most cases
have been assessed by a maximal CPET and communi-
cated to the physical therapist in order to enable the
physical therapist to construct a safe and tailored-made
programme for the patient. If the clinical status of the
patient in the RCT is not yet assessed in the hospital or
rehabilitation clinic, the treating physical therapist will
be asked to refer the patient for a maximal CPET to a
sports medicine physician, who is contacted by the
researcher.
After the baseline visit, participants in the cohort
will be assessed every three months for 12 months or
longer. Participants from both the experimental and
the control group in the RCT will be measured at
three and six weeks, and three, six, twelve and
twenty-four months during follow-up visits at the
physical therapy practice for various outcome mea-
sures (Figure 3).
In the RCT, prospective daily diary cards are distributed
every month for twenty-four consecutive months and are
returned by the patient at the end of every month. The
retrospective questionnaire on the use of health care is
send to the patient once every three months for twenty-
four consecutive months.
Figure 3 Planning of outcome measurements in the RCT. The diary cards are not included in the Figure, but they are used by the patient
every day of every month until T6. In the cohort, the baseline measurement is followed by the same measurements as on T3 in the RCT and are
repeated every three months for at least twelve consecutive months. Definition of abbreviations: T0 = baseline measurement; T1 – T10 = consecutive
measurements in time after the baseline measurement; A = Anthropometric measures; B = Bicycle test results (maximal cardiopulmonary exercise test
(CPET)); S = Spirometry results; 6 = 6MWT+ Borg score and mGUG+ Borg; M = peripheral muscle strength; P = physical activity in daily life with
accelerometer; Q = CCQ*, CRQ-SR, EQ-5D*, DS14, MRC and level of effective mucus clearance, level of motivation, physical activity, physical therapy
compliance*; C = questionnaire to assess direct and indirect costs; and G = Global Perceived Effect*. Measurement occasions are explained in the Table
above the Figure. *The only measurements on T1 and T2.
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Clinical effectiveness
The descriptive characteristics are presented quantitatively
as mean (±standard deviation) or median (5th - 95th per-
centile), depending on the data distribution, whenever the
variable is continuous or as a percentage whenever the
variable is dichotomous or categorical. Data will be ana-
lysed with SPSS-19. Assumptions accompanying the fol-
lowing statistical methods will be checked and all data
analyses will be applied by a blinded analyst.
Data from the RCT will be analysed to examine inter-
vention main effect on the counts for the primary out-
come (exacerbation frequency) and the secondary
outcomes. All exacerbations from each patient will be
used as the dependent outcome to evaluate the effect
of physical therapy at the end of the intervention
(12 months) and follow-up (24 months). Measurementmoments for secondary outcomes are baseline, three
and six weeks, three, six, twelve and twenty-four weeks.
The effects of the variable of primary interest, physical
therapy (pdPT), will be analysed in a generalized linear
model (GLM) for group (intervention vs. control) ana-
lysis of covariance with adapted regression for count
data distribution. Analyses of secondary outcomes will
be done with linear regression analysis and generalized
linear models. Since exacerbation outcome in the RCT
is measured with two methods, analyses will be based on
the event-based approach, on the symptom-based ap-
proach and on a combination of both. Potential con-
founding by variables like, age, gender, GOLD stage,
smoking, physical activity in daily life, exacerbation his-
tory, severity of latest exacerbation, and comorbidity,
will be controlled for. Results from a ‘per-protocol’ and
an ‘intention-to-treat’ principle will be compared. At a
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0.05 will be considered as significant.
Economic evaluation
From the RCT data cost-effectiveness and a cost-utility
of physical therapy in COPD patients experiencing exac-
erbations compared to usual care will be established
using a one and two year time horizon.
A cost-effectiveness analysis will be performed, weigh-
ing incremental costs against the mean incremental ef-
fect in terms of quality of life based. For assessing
patient outcome, the score of the disease specific quality
of life measures CCQ and CRQ-SR will be used at the
12 months follow up moment. For this purpose, a soci-
etal perspective will be administered, indicating the rele-
vance of direct medical, direct non-medical and indirect
costs, as adding measurement of indirect costs will pro-
vide a more comprehensive picture of the burden of ex-
acerbations [55]. For defining the content of care
‘consumed’, out of pocket costs, lost productivity costs
and direct non-medical costs for each patient in the
RCT, resource use will be measured using patient ques-
tionnaires. These frequently used retrospective question-
naires will cover a three months retrospective period.
Moreover, patients’ daily diary cards will be assessed, to
incorporate each exacerbation experienced by a patient
that involves ‘consumed’ care. The costs of the experimen-
tal physical therapy will be assessed using micro-costing
and time-and-motion techniques in several participating
practices and patients’ dossiers of the physical therapist
will be assessed.
For the cost-utility analysis, quality adjusted life year
(QALY) will be calculated based on the EuroQol ques-
tionnaire (EQ-5D-3L). The EQ-5D-3L is a generic qual-
ity instrument that will make it able to calculate utilities
at each outcome measurement (on a 12 months’ and
24 months’ basis). Thus, societal cost will be used to cal-
culate the incremental cost-effectiveness based on CCQ
and CRQ-SR and to calculate the incremental cost-
utility based on QALYs. Besides, the cost of the physical
therapy intervention will be assessed against the inci-
dence of exacerbation in both groups within the RCT.
Project time frame
The project in total will take five years. During the first
three years of the project, physical therapy practices
and COPD patients will be recruited. Patients in the
cohort will be followed at least until the end of the pro-
ject. Patients included in the RCT will be followed for
two years by means of the COPD-specific electronic pa-
tient record system, while the treatment will be one
year. The last year of the project is reserved for the pro-
cessing and analysis of data, as well as the publication
of results.Discussion
In this article the protocol of a cohort-nested rando-
mised controlled trial is presented, concerning a study
about the effect and cost-effectiveness of standardised
physical therapy as a supportive measure to prevent or
postpone future exacerbations, to shorten the duration
or to decrease the severity of future exacerbations in
COPD patients experiencing acute exacerbations. The
focus on prevention of exacerbations by means of phy-
sical therapy fits one of the prime management goals for
COPD, which is ‘reducing the frequency of hospitalisa-
tions due to exacerbations’ [1]. It is expected that the
outcomes of this study will provide useful information
about the effects of physical therapy on exacerbations,
which may alter the role of physical therapy in managing
COPD in the future.
Healthcare utilisation is not an optimal substitute for
exacerbation frequency, exacerbation duration and ex-
acerbation severity, depending on many unrelated social
factors and comorbidity. It is an outcome in its own
right [45]. Therefore, not only will this event based ap-
proach be applied in this trial, also a symptom based
approach will be used. Both approaches will be used
separately and together and their influence on outcome
will be compared during statistical analyses.
Bias and confounding
To assure a high quality treatment according to KNGF
guidelines physical therapy for COPD, the participating
physical therapists will be trained before the start of the
study. It is obvious that physical therapists as well as pa-
tients cannot be fully blinded during this study, since
both groups are aware of the treatment procedures.
Moreover, due to practical reasons physical therapists
perform some exercise measurements instead of the re-
searcher. This can lead to subjective interpretations of
the research findings. Therefore, participating physical
therapists will be instructed to make correct use of the
measurement instruments for standardisation. To min-
imise social desirability answering, patients are told that
there are no right or wrong answers before filling out
questionnaires. In order to minimize differential Haw-
thorne effects, all patients from the cohort, the interven-
tion group and the control group in the RCT will be
monitored very precisely in a standardised way on first
signs of exacerbations and other outcome measurements.
To minimise bias, research findings will be analysed by a
blinded researcher.
Potential problems
Potential problems regarding the execution of this study
are twofold. Because COPD is a complex disease the
KNGF guidelines for physical therapy for COPD pa-
tients requires a lot of effort from participating physical
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general KNGF Guidelines on Reporting in Physical
Therapy. Although the outcome measures in this study
are very well connecting to the requirements of these
guidelines, complete registration remains difficult and
costs time, so problems may be expected regarding the
full registration of COPD patients in this study.
Besides, patients who enter the RCT may be assigned
to the control group, which may come with some prob-
lems. To include patients in the control group means
physical therapists are only allowed to offer no or very
low-intensity exercise training. Due to the lower frequency
of treatments, participation in the RCT may be financially
unattractive to the physical therapy practice and physical
therapists. Moreover, there is a chance that patients in the
intervention group of the RCT are doing much better
compared to the control group.
Additional file
Additional file 1: Description of the main goals and content of the
protocol-directed physical therapy intervention for a patient with
COPD within the cohort-nested RCT, according to a framework
based on the International Classification of Functioning, Disability
and Health (ICF). Description: An evidence-based framework for describing
goals and content of exercise intervention. The framework that is developed
by van der Leeden and colleagues (2013) is a response to the requirements
by the CONSORT statement for precise detail of interventions and provides
structure for use in research reports [44].
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